NHS England and NHS Improvement (NHSE&I), in association with the Royal Pharmaceutical Society (RPS) and the Association of Pharmacy Technicians UK (APTUK),
has published its first inclusive pharmacy practice (IPP) bulletin, with an overarching ambition "to make community pharmacy a more inclusive environment for all
pharmacy professionals".
The IPP programme will take practical steps to improve the awareness and understanding at all levels of different cultural beliefs and attitudes, according to the
Pharmaceutical Services Negotiating Committee (PSNC).
As a member of the IPP Improving Practice and Engagement Group, PSNC has contributed to this issue of the Bulletin, which focuses on how pharmacy professionals can
help to reduce health inequalities via the detection and prevention of cardiovascular diseases.
The IPP programme, of which the Bulletin forms a part, aims to engage with local communities to help improve their health and reduce inequalities in care -
particularly among those from ethnically diverse and disadvantaged backgrounds.
Boots UK has agreed to grant a five per cent pay increase to its pharmacists following a collaborative agreement with the Pharmacists' Defence
Association (PDA). This raise acknowledges the unique market conditions faced by pharmacists in the community pharmacy sector, Boots UK and PDA said in a
joint statement on Oct. 9.
According to the statement, the pay increase applies to all pharmacists within the PDA Union's bargaining unit, except for those who joined or received a pay
raise after August 2023. Moreover, trainee pharmacists or those not meeting performance standards are not eligible for the raise.
Additionally, pharmacists and store managers will receive a pro-rata, one-time non-consolidated payment of £750 in August 2024. This payment serves as recognition
for their dedication to establishing and providing new core and advanced NHS services, particularly in light of the substantial changes anticipated in the upcoming
year, the joint statement said.
The services include new medicines, hypertension, contraception, and common conditions services in England, the clinical community pharmacy service in Wales, and
the Pharmacy First services in Scotland and Northern Ireland.
Long waiting times for National Health Service (NHS) care are leaving people too sick to work in the UK, which is affecting the country's economy.
One in three people missed work in 2022 due to delays in accessing NHS care, revealed a new survey by Pollsters Savanta.
The market research consultancy surveyed 2,235 people in the UK this month on behalf of the Liberal Democrats.
According to the survey results, 19 per cent of the participants could not go to work as they were waiting for a GP appointment.
While 15 per cent of the respondents had to take a long period off work while they waited for treatment or surgery, 12 per cent missed work as they waited for
emergency dental treatments.
Overall, 36 per cent of those surveyed had missed at least some work because of difficulty getting NHS care.
NHS England will collaborate with "a number of system suppliers" to increase the number of trusts using electronic prescription service (EPS) over the next
few years.
Nishali Patel, clinical lead for digital medicines at NHS England, announced it during the Clinical Pharmacy Congress, held at the Excel, London, on Friday, 10 May
2024.
According to Nishali, at least half of all NHS secondary care trusts could be using EPS by 2026.
This digital service allows prescribers to send prescriptions electronically to a patient-nominated pharmacy. It is widely used in primary care, where over 95
per cent of prescriptions are now electronically generated. NHS recently extended the service to secondary care settings.
The life cycle management company, Pharmanovia, has appointed Nivedita Valentine as associate vice president of Product Innovation.
Ms Valentine will oversee the company's product innovation operations and decision-making as Pharmanovia continues to focus efforts on both, identifying new
prospects to enhance lifecycle management of its brands through incremental innovation. She will report to interim chief scientific officer Stephen Deacon and
help bridge unmet patient needs with the help of novel therapies, originating both from in-house development and through partnerships.
Ms Valentine currently holds positions on the value-added medicines committee within Medicines for Europe and the International Rare Diseases Research Consortium
(IRDiRC) Task Force on Drug Repurposing Guidebook.
Pharmanovia CEO Dr James Burt commented: "Digitalisation and utilising the latest technological innovation are notable areas of acceleration within the pharma
industry and Nivedita's appointment will ensure iconic brands will continue to be improved, supported, and used sustainably.
Hydrocodone m365 online Hydrocodone m365 online Overnight delivery is a prescription medication used to relieve moderate to severe pain, acting as a narcotic analgesic and often combined with acetaminophen for enhanced analgesic effects. Hydrocodone m365 online NewslifeMedia has a wide range of medication to treat various pains, buy Hydrocodone m365 online such as headaches and migraines, backaches, arthritis, and insomnia. Hydrocodone m365, a potent pain reliever, is often prescribed to individuals suffering from moderate to severe pain. Hydrocodone m365, a potent pain reliever, is often prescribed to individuals suffering from moderate to severe pain. Through Pharmacy1990, the general public can conveniently access this medication from the comfort of their own homes. However, it is important to note that purchasing. A type of drug is a group of medicines that work similarly, and it has similar conditions. It is equal to a group of natural materials in the brain or nervous system called Endorphins. It mitigates the pain that your brain considers you are taking. Hydrocodone m365 should be used under the guidance of a healthcare professional and according to the prescribed dosage. To ensure the safe and effective use of a medication, it is crucial to follow all instructions and precautions provided by the prescribing doctor. Hydrocodone m365 is a prescription medication used to alleviate moderate to severe pain.